MedPath

Myosin Therapeutics Secures $3M in Second Seed Funding to Advance Brain Cancer and Addiction Therapies

• Myosin Therapeutics has raised over $3 million in its second seed round, complementing NIH funding to advance clinical trials for glioblastoma and methamphetamine use disorder treatments.

• The company's lead compound MT-125, which targets molecular nanomotors to block tumor growth, has received FDA orphan drug designation for malignant gliomas and will enter Phase 1b trials.

• MT-110, the company's novel treatment for methamphetamine use disorder, is set to begin Phase 1 clinical trials, addressing a critical gap in FDA-approved treatments for this condition.

Jupiter, Florida-based Myosin Therapeutics has secured over $3 million in its second seed funding round, positioning the company to advance its innovative pipeline of cancer and neuroscience therapies into clinical trials. The funding round, supplemented by National Institutes of Health support, attracted investment from prominent healthcare venture firms and strategic partners.
The company's flagship program centers on MT-125, a novel compound targeting molecular nanomotors to combat glioblastoma, one of the most aggressive forms of brain cancer. With current treatments offering limited efficacy and an average survival time of only 8 months, MT-125 represents a potential breakthrough in addressing this devastating disease. The FDA has already recognized the compound's promise by granting it orphan drug designation for malignant gliomas.
"This funding is pivotal as it will allow us to initiate multiple clinical trials this year, including a Phase 1b trial for MT-125 in glioblastoma patients," said Dr. Courtney Miller, co-founder and CEO of Myosin Therapeutics. The company's innovative approach focuses on blocking both tumor growth and invasion through its unique molecular mechanism.

Strategic Investment Partners

The funding round was led by returning investors DeepWork Capital, Florida Opportunity Fund, and Mint12 Pharma, with new participation from Dynagrow Capital, Mayo Clinic Ventures, and The Sontag Innovation Fund. Dave Adams, co-Founder of Mint12 Pharma, expressed confidence in the company's trajectory, noting, "Myosin Therapeutics exemplifies a well-run organization, consistently achieving key milestones to advance MT-125 and MT-110."

Expanding into Addiction Treatment

Beyond oncology, Myosin Therapeutics is developing MT-110 for methamphetamine use disorder (MUD), addressing a significant unmet medical need. Despite millions worldwide suffering from MUD, there are currently no FDA-approved treatments available. The new funding will enable the company to initiate Phase 1 clinical trials for MT-110, potentially offering the first approved therapeutic option for this challenging condition.

Scientific Foundation and Future Direction

The company, which emerged from The Herbert Wertheim UF Scripps Institute, leverages its proprietary platform targeting molecular nanomotor proteins to develop therapeutic solutions. This unique approach has positioned Myosin Therapeutics at the forefront of both oncology and neuroscience drug development, with potential applications across multiple devastating diseases.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Sterotherapeutics Launches Phase 2 Trial of Novel Cushing's Syndrome Treatment ST-002

Sterotherapeutics initiates Phase 2 clinical trial of ST-002, a novel drug candidate for Cushing's syndrome, with an Investigators Meeting scheduled in Athens, Greece on February 24, 2025.
The FDA has granted orphan drug designation to ST-002, providing regulatory incentives and seven years of post-approval marketing exclusivity for this rare endocrine disorder treatment.

Miist Therapeutics Secures $7M Seed Funding for Ultra-Rapid Inhaled Drug Delivery Platform

Miist Therapeutics has developed a revolutionary inhaler technology that delivers drugs to the bloodstream 100 times faster than oral medications, with Phase 1 trials showing 92% symptom relief in 2 minutes.
The company's proprietary inhaler creates sterile aqueous drug particles using vibration technology, achieving peak plasma drug levels in under 30 seconds through peripheral lung delivery.

MindBio's Phase 2B Trials of MB22001 Microdosing Show Positive Safety Profile

MindBio's Phase 2B trials of MB22001 for major depressive disorder and advanced-stage cancer have passed a mandatory safety audit.
The independent review found no serious adverse events, allowing the trials to proceed as planned toward completion in late 2025.

Kinoxis Therapeutics Receives $2.5M Grant to Advance KNX100 for Dementia Agitation

Kinoxis Therapeutics secured a $2.5 million grant to support its Phase 2a CARES-X clinical trial of KNX100 for dementia-related agitation.
The CARES-X trial, involving eight Australian sites, will assess KNX100's safety, tolerability, and efficacy over a four-week period.

Doron Therapeutics Secures $11M to Advance MOTYS for Knee Osteoarthritis into Phase 3 Trial

Doron Therapeutics has raised $11 million in Series A funding to support a Phase 3 clinical trial of MOTYS, a novel intra-articular biologic drug for symptomatic knee osteoarthritis.
MOTYS, derived from placental tissue, aims to provide anti-inflammatory, anti-catabolic, and pro-anabolic effects through growth factors, offering a potential alternative to corticosteroids and hyaluronic acid.

Mito Fund Invests in Khondrion to Advance Sonlicromanol for Primary Mitochondrial Disease

The Mito Fund has invested in Khondrion to support the Phase III development of sonlicromanol, a drug candidate for primary mitochondrial disease (PMD).
Sonlicromanol targets key metabolic and inflammatory pathways and has shown benefits in Phase IIb trials for PMD patients with the m.3243A>G mutation.

MB-105, a CD5-Targeted CAR-T Cell Therapy, Receives FDA Orphan Drug Designation for T-Cell Lymphoma

March Biosciences' MB-105, a first-in-class CD5 CAR-T cell therapy, has received FDA Orphan Drug Designation for relapsed/refractory CD5-positive T-cell lymphoma.
The Orphan Drug Designation provides incentives including tax credits, user fee exemptions, and seven years of market exclusivity post-approval.

Moleculin Biotech's STAT3 Inhibitor WP1066 Enters Phase 2 Trial for Glioblastoma

Moleculin Biotech initiates a Phase 2 trial of WP1066, a STAT3 inhibitor, combined with radiation for glioblastoma treatment at Northwestern University.
The trial (NU 21C06) is an open-label, multi-arm study focusing on newly diagnosed IDH wild-type, MGMT-unmethylated glioblastoma patients.

Breakthrough in Glioblastoma Treatment Research at Mayo Clinic

Mayo Clinic researchers have made significant progress in the search for effective glioblastoma therapies, developing a treatment with a nearly 50% cure rate in laboratory models. This innovative approach combines a small molecule inhibitor with an FDA-approved drug, showing promising results without adverse effects. The research focuses on targeting molecular motors and overcoming drug resistance, offering new hope for treating this lethal brain tumor.

Tonix Pharmaceuticals' Tonmya™ Receives Conditional FDA Acceptance for Fibromyalgia Treatment

Tonix Pharmaceuticals' TNX-102 SL, conditionally named Tonmya™, has received FDA acceptance as a trade name for fibromyalgia management.
Two positive Phase 3 trials demonstrated Tonmya's potential as a novel, first-line treatment option for fibromyalgia, affecting millions in the U.S.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy